Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
2
|
| gptkbp:bfsParent |
gptkb:physicist
|
| gptkbp:acquired |
gptkb:Bayer_AG
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:collaborations |
academic institutions
research organizations |
| gptkbp:focus |
gptkb:drug
|
| gptkbp:focus_area |
gptkb:Company
gptkb:municipality quality assurance patient safety regulatory compliance biomarker discovery data analytics patient engagement personalized medicine market access clinical research biostatistics preclinical studies therapeutic development clinical outcomes therapeutic efficacy post-marketing surveillance health economics patient-reported outcomes real-world evidence commercialization biomanufacturing regulatory affairs healthcare partnerships clinical trials management healthcare policy. therapeutic validation |
| gptkbp:founded |
gptkb:2016
|
| gptkbp:founder |
gptkb:Hans_Bishop
|
| gptkbp:goal |
developing innovative therapies.
|
| gptkbp:headquarters |
gptkb:Toronto,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Blue Rock Therapeutics
|
| gptkbp:investment |
gptkb:Series_A
gptkb:Series_B $225 million |
| gptkbp:leadership |
gptkb:Hans_Bishop
gptkb:Michael_Kauffman gptkb:David_Kessler gptkb:Kevin_Mc_Cormack |
| gptkbp:location |
gptkb:North_America
|
| gptkbp:mission |
transforming the treatment of degenerative diseases.
|
| gptkbp:partnership |
gptkb:Bayer_AG
gptkb:Bayer's_Pharmaceuticals_Division |
| gptkbp:platform |
cell differentiation
cell engineering cell manufacturing |
| gptkbp:products |
cell-based therapies
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved |
| gptkbp:research_focus |
gptkb:psychologist
neurological disorders cardiovascular diseases heart disease |
| gptkbp:specializes_in |
regenerative medicine
|
| gptkbp:technology |
induced pluripotent stem cells
|
| gptkbp:type |
private company
|
| gptkbp:website |
bluerocktherapeutics.com
|